ASX Share rice
Sun 16 May 2021 - 12:38:am (Sydney)

CLV Share Price

CLOVER CORPORATION LIMITEDCLVMaterials

CLV Company Information

Name:

Clover Corporation Limited

Sector:

Consumer Defensive

Industry:

Packaged Foods

GIC Industry:

Chemicals

GIC Sub Industry:

Specialty Chemicals

Address:

39 Pinnacle Road Altona North VIC Australia 3025

Phone:

61 3 8347 5000

Full Time Employees:

49

CEO, MD & Director:

Mr. Peter J. Davey M.B.A., MBA, gradDip Bus., GAICD

CFO & Company Sec.:

Mr. Paul A. Sherman C.A., M.B.A., B.Bus, CA, MBA

Operations Mang.:

Mr. David Pierotti

Human Resource & Payroll Mang.:

Ms. Sharon Brewster

Chief Commercial Officer:

S. Poothong

Company Overview:

Clover Corporation Limited refines and sells natural oils in Australia, New Zealand, Asia, Europe, and the Americas. The company is also involved in the production of encapsulated powders; and research and product development of functional food and infant nutrition ingredients. It offers Nu-Mega Hi docosahexaenoic acid tuna oils for use in infant formula and pharmaceutical products; Ocean Gold refined tuna oils; Nu-Mega Driphorm powders that are used in a range of infant formula, follow-on formula, growing up milks, and food applications; and Nu-Mega Driphorm HA for non-dairy applications. The company was founded in 1988 and is headquartered in Altona North, Australia.

CLV Share Price Information

Shares Issued:

166.31M

Market Capitalisation:

$254.45M

Dividend per Share:

$0.03

Ex Dividend Date:

2021-04-07

Dividend Yield:

1.96%

Revenue (TTM):

$80.10M

Revenue Per Share (TTM):

$0.48

Earnings per Share:

$0.062

Profit Margin:

0.1294

Operating Margin (TTM):

$0.21

Return On Assets (TTM):

$0.14

Return On Equity (TTM):

$0.20

Quarterly Revenue Growth (YOY):

-0.217

Gross Profit(TTM):

$29.72M

Diluted Earnings Per Share (TTM):

$0.062

QuarterlyEarnings Growth(YOY):

-0.46

CLV CashFlow Statement

CashFlow Date:

2020-07-31

Investments:

$-3,461,000

Change To Liabilities:

$-2,073,000

Total Cashflow From Investing Activities:

$-4,017,000

Net Borrowings:

$1.24M

Net Income:

$12.49M

Total Cash From Operating Activities:

$6.66M

Depreciation:

$679K

Other Cashflow From Investing Activities:

$-3,461,000

Dividends Paid:

$-2,910,000

Change To Inventory:

$-4,252,000

Change To Account Receivables:

$1.67M

Capital Expenditures:

$556K

CLV Income Statement

Income Date:

2020-07-31

Income Before Tax:

$17.66M

Net Income:

$12.49M

Gross Profit:

$29.72M

Operating Income:

$18.29M

Interest Expense:

$588K

Income Tax Expense:

$5.17M

Total Revenue:

$88.28M

Cost Of Revenue:

$58.57M

CLV Balance Sheet

Balance Sheet Date:

2020-07-31

Total Liabilities:

$23.92M

Total Stockholder Equity:

$57.57M

Other Current Liabilities:

$2.30M

Total Assets:

$81.49M

Common Stock:

$35.37M

Other Current Assets:

$1.12M

Retained Earnings:

$21.96M

Other Liabilities:

$77K

Good Will:

$1.91M

Other Assets:

$1.08M

Cash:

$9.24M

Total Current Liabilities:

$10.94M

Property - Plant & Equipment:

$5.85M

Net Tangible Assets:

$55.66M

Long-Term Investments:

$13.58M

Total Current Assets:

$59.07M

Long-Term Debt:

$12.90M

Net Receivables:

$16.78M

Short-Term Investments:

$22.41M

Inventory:

$31.93M

Accounts Payable:

$6.30M

Short-Term Investments:

$22.41

Non Current Liabilities Total:

$12.98M

CLV Share Price History

CLV News

27 Apr, 2021
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
22 Mar, 2021
One thing we could say about the analysts on Clover Corporation Limited ( ASX:CLV ) - they aren't optimistic, having...
10 Mar, 2021
With its stock down 25% over the past three months, it is easy to disregard Clover (ASX:CLV). But if you pay close...
12 Feb, 2021
A look at the shareholders of Clover Corporation Limited ( ASX:CLV ) can tell us which group is most powerful. Large...
17 Jan, 2021
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
18 Dec, 2020
This article will reflect on the compensation paid to Peter Davey who has served as CEO of Clover Corporation Limited...
18 Nov, 2020
Clover Corporation Limited (ASX:CLV), might not be a large cap stock, but it saw significant share price movement...
23 Oct, 2020
Clover Corporation Limited (ASX:CLV) is about to trade ex-dividend in the next three days. If you purchase the stock...
22 Oct, 2020
The analysts covering Clover Corporation Limited (ASX:CLV) delivered a dose of negativity to shareholders today, by...
15 Oct, 2020
Clover Corporation Limited (ASX:CLV) shareholders might be concerned after seeing the share price drop 11% in the last...
30 Sep, 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the addition of Nils Lonberg, Ph.D., to its Scientific Advisory Board (SAB). Dr. Lonberg is a pioneer in the field of immuno-oncology and has more than 30 years of experience in the biopharmaceutical industry. Concurrently, Charles (Chuck) Drake, M.D., Ph.D. will be stepping down from Compugen's SAB to pursue a new pharmaceutical industry role. Prof. Drake has served as a member of Compugen's SAB since 2013.
19 Sep, 2020
Clover Corporation Limited (ASX:CLV) came out with its annual results last week, and we wanted to see how the business...
18 Sep, 2020
Clover Corporation Limited's (ASX:CLV) price-to-earnings (or "P/E") ratio of 36.3x might make it look like a strong...
08 Sep, 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the Phase 1/2 study evaluating the triple combination of COM701, Compugen's first-in-class anti-PVRIG antibody, with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), and their investigational anti-TIGIT antibody, BMS-986207.
03 Sep, 2020
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the following upcoming virtual investor conferences:
28 Aug, 2020
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent covering the composition of matter of COM902, its immuno-oncology therapeutic antibody targeting TIGIT.
30 Jul, 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial results for the second quarter ended June 30, 2020.
16 Jul, 2020
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the Company will release its second quarter 2020 financial results on Thursday, July 30, 2020 before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.
26 May, 2020
Clover Corporation Limited (ASX:CLV), which is in the chemicals business, and is based in Australia, led the ASX...

CLV Dividend Payments

EX-Date Dividend Amount
2010-11-29$0.0125
2011-10-27$0.0150
2012-10-26$0.0175
2013-04-16$0.0050
2013-10-25$0.0150
2014-04-16$0.0050
2014-10-29$0.0050
2015-10-28$0.0050
2016-04-11$0.0025
2016-10-27$0.0050
2017-04-10$0.0025
2017-10-27$0.0075
2018-04-09$0.0050
2018-10-29$0.0125
2019-04-08$0.0063
2019-10-29$0.0175
2020-10-27$0.0250
2021-04-07$0.0050

CLV Dividends (last 12 Years)